<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="23" ids="18059">Lipid</z:chebi> and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> abnormalities have been implicated in the pathogenesis of ischemic cerebrovascular disease and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="1" ids="6495">Lipoprotein</z:chebi> lipase (LPL) plays an important role in plasma <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> metabolism </plain></SENT>
<SENT sid="2" pm="."><plain>Several studies have recently reported the presence of a relationship between Ser447Stop mutation of LPL and <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Other polymorphisms (HindIII and PvuII) of the LPL gene have already been shown to correlate significantly with <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We investigated whether these polymorphisms are associated with increased risk of ischemic cerebrovascular disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: We recruited 177 CVD patients (atherothrombotic infarction, n=71; cardioembolic infarction, n=30; <z:e sem="disease" ids="C0333559" disease_type="Disease or Syndrome" abbrv="">lacunar infarction</z:e>, n=76) and 177 healthy control subjects </plain></SENT>
<SENT sid="6" pm="."><plain>Subjects were genotyped for the Ser447Stop mutation and for HindIII/PvuII restriction fragment length polymorphisms of the LPL gene, and the findings were investigated for associations with the clinical subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and with <z:chebi fb="23" ids="18059">lipid</z:chebi> levels </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The Ser447Stop mutation correlated significantly with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> (0.107 versus 0.158; P=0.035) </plain></SENT>
<SENT sid="8" pm="."><plain>For the CG+GG versus CC genotype, the odds ratio between control subjects and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> patients with atherothrombotic infarction was 0.42 (95% CI, 0.18 to 0.99) (P=0.046) </plain></SENT>
<SENT sid="9" pm="."><plain>Serum <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels did not correlate significantly with the Ser447Stop genotype </plain></SENT>
<SENT sid="10" pm="."><plain>HindIII polymorphism correlated significantly with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> (0.234 versus 0.169; P=0.031), but the frequency of PvuII polymorphism was not significantly different between groups </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Our results suggest that the Ser447Stop mutation of the LPL gene is a novel genetic marker for low risk of atherothrombotic <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
</text></document>